4.7 Article

Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis

期刊

ANNALS OF NEUROLOGY
卷 75, 期 3, 页码 411-428

出版社

WILEY
DOI: 10.1002/ana.24117

关键词

-

资金

  1. Dutch Cancer Society
  2. ErasmusMC fellowship
  3. Fonds zur Forderung der wissenschaftlichen Forschung, Austria [J3230, W1206, I916]
  4. Forschungsforderungsfonds Hamburg Eppendorf Exzellenzjahr
  5. NIH National Institute of Neurologic Disorders and Stroke [RO1NS077851]
  6. McKnight Neuroscience of Brain Disorders award
  7. Fundacio la Marato TV3 [101530, 101610]
  8. Fondo de Investigaciones Sanitarias de la Seguridad Social, Spain [PI11/01780]
  9. A National MS Society
  10. Ministry of Education, Culture, Sports, Science, and Technology of Japan [25461297]
  11. Kinki University
  12. Austrian Science Fund (FWF) [I916, J3230] Funding Source: Austrian Science Fund (FWF)
  13. Grants-in-Aid for Scientific Research [25461297] Funding Source: KAKEN
  14. Austrian Science Fund (FWF) [I 916] Funding Source: researchfish
  15. ICREA Funding Source: Custom

向作者/读者索取更多资源

Objective To report the clinical, radiological, and immunological association of demyelinating disorders with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis. Methods Clinical and radiological analysis was done of a cohort of 691 patients with anti-NMDAR encephalitis. Determination of antibodies to NMDAR, aquaporin-4 (AQP4), and myelin oligodendrocyte glycoprotein (MOG) was performed using brain immunohistochemistry and cell-based assays. Results Twenty-three of 691 patients with anti-NMDAR encephalitis had prominent magnetic resonance imaging (MRI) and/or clinical features of demyelination. Group 1 included 12 patients in whom anti-NMDAR encephalitis was preceded or followed by independent episodes of neuromyelitis optica (NMO) spectrum disorder (5 cases, 4 anti-AQP4 positive) or brainstem or multifocal demyelinating syndromes (7 cases, all anti-MOG positive). Group 2 included 11 patients in whom anti-NMDAR encephalitis occurred simultaneously with MRI and symptoms compatible with demyelination (5 AQ4 positive, 2 MOG positive). Group 3 (136 controls) included 50 randomly selected patients with typical anti-NMDAR encephalitis, 56 with NMO, and 30 with multiple sclerosis; NMDAR antibodies were detected only in the 50 anti-NMDAR patients, MOG antibodies in 3 of 50 anti-NMDAR and 1 of 56 NMO patients, and AQP4 antibodies in 48 of 56 NMO and 1 of 50 anti-NMDAR patients (p < 0.0001 for all comparisons with Groups 1 and 2). Most patients improved with immunotherapy, but compared with anti-NMDAR encephalitis the demyelinating episodes required more intensive therapy and resulted in more residual deficits. Only 1 of 23 NMDAR patients with signs of demyelination had ovarian teratoma compared with 18 of 50 anti-NMDAR controls (p = 0.011). Interpretation Patients with anti-NMDAR encephalitis may develop concurrent or separate episodes of demyelinating disorders, and conversely patients with NMO or demyelinating disorders with atypical symptoms (eg, dyskinesias, psychosis) may have anti-NMDAR encephalitis. Ann Neurol 2014;75:411-428

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据